ArticleParasites & vectors2026
Evolving patterns of antimalarial drug resistance markers in symptomatic infections in Kenya, 2013-2022.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOngoing antimalarial drug resistance surveillance is essential to guide effective treatment strategies. Historically, resistance to chloroquine and sulfadoxine-pyrimethamine (SP) has been associated with well-characterized mutations in the chloroquine resistance transporter (Pfcrt; K76T) and antifolate pathway genes, including dihydrofolate reductase (Pfdhfr; N51I, C59R, S108N) and dihydropteroate synthase (Pfdhps; A437G, K540E, A581G). Since the introduction of artemisinin-based combination therapies (ACTs), 13 mutations in the kelch 13 (PfK13) propeller domain have emerged as World Health Organization (WHO) validated markers of partial artemisinin resistance. This study aimed to characterize temporal trends in both established, Pfcrt and Pfk13, and less well-described potential markers, cysteine desulfurase (Pfnfs) and Pfcoronin, using febrile malaria samples collected across diverse regions of Kenya between 2013 and 2022.
methodsThe temporal trend of these markers of resistance were assessed by screening archived P. falciparum-positive dried blood spots (DBS). A total of 1750 DBS samples were collected from therapeutic efficacy studies (TES) conducted across distinct malaria transmission settings in Kenya, including coastal Kenya (Kwale 2013, n = 350; 2018, n = 150), the lake endemic region of Western Kenya (Kisumu 2015, n = 314; Busia 2016, n = 334), and the highland epidemic region of western Kenya (Kisii 2017, n = 314). Additional samples were obtained from an hrp2 study conducted in Kisii in 2022, (n = 288). Parasite genomic DNA was extracted using the Chelex-saponin method and confirmed by a Pf18S real-time polymerase chain reaction (RT-PCR). Pfk13, Pfcrt, Pfnfs, and Pfcoronin PCR amplicons were sequenced using capillary electrophoresis, Illumina Miseq or Oxford Nanopore (GridION) platforms.
resultsThe prevalence of Pfcrt mutations declined over time and no WHO-validated Pfk13 mutations associated with artemisinin resistance were detected. However, synonymous substitutions at WHO-validated codons C469C and P553P were identified. In the Pfcoronin gene, nonsynonymous mutations distinct from those reported in West Africa were observed at high frequencies (> 75%). Notably, the Pfnfs-K65Q mutation, previously associated with reduced lumefantrine sensitivity in West Africa, was detected in more than 80% of the samples.
conclusionsOur findings reveal no WHO-validated k13 mutations up until 2022 and confirm previous findings of a reduction in the Pfcrt resistance genotypes over time. This study underscores the importance of continued molecular surveillance and suggests that resistance may evolve through different pathways in East compared with West Africa and Southeast Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.